Sepracor taps Adams as CEO

Share this article:
Sepracor named Adrian Adams CEO, replacing Timothy Barberich, who was elected executive chairman of the company’s board of directors. Adams appointment had been anticipated since his hiring as COO on March 1. Adams, who will retain title of president, was previously CEO at Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. Adams is a 30-year veteran of the pharmaceutical industry with experience in national and international product marketing, R&D, sales, business development and general management with companies including ICI, SmithKline Beecham and Novartis.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...